Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 22, 2015

Adjuvant Sorafenib and Sunitinib and Cardiotoxicity in Renal Cell Carcinoma Patients Without Overt Metastases

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients Without Overt Metastases: Results From ASSURE, ECOG2805
Clin. Cancer Res 2015 May 12;[EPub Ahead of Print], N Haas, J Manola, B Ky, KT Flaherty, RG Uzzo, C Kane, MA Jewett, L Wood, CG Wood, MB Atkins, JP Dutcher, G Wilding, R DiPaola

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading